Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis

International Journal of Pharmaceutics

Volumn 528, Issue 1-2, 2017, Pages 107-117

  Momin, Mohammad A M ^a   Sinha, Shubhra ^a   Tucker, Ian G ^a   Doyle, Colin ^b   Das, Shyamal C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Dry powder inhaler; Hygroscopic; Kanamycin; L leucine; Spray drying; Tuberculosis

Indexed keywords

EXCIPIENT; KANAMYCIN; LEUCINE;

A-549 CELL LINE; AEROSOL; ARTICLE; CALU 3 CELL LINE; CHEMICAL COMPOSITION; CHEMICAL INTERACTION; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CRYSTALLIZATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESISTANT TUBERCULOSIS; DRY POWDER; IN VITRO STUDY; INFRARED SPECTROSCOPY; LASER DIFFRACTION; LUNG CELL LINE; MOISTURE; MTT ASSAY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SURFACE PROPERTY; THERMOGRAVIMETRY; WATER CONTENT; X RAY DIFFRACTION; X RAY PHOTOELECTRON SPECTROSCOPY; DRY POWDER INHALER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; POWDER; TUMOR CELL LINE;

ADMINISTRATION, INHALATION; AEROSOLS; CELL LINE, TUMOR; DRY POWDER INHALERS; HUMANS; KANAMYCIN; PARTICLE SIZE; POWDERS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85020237840     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2017.06.004     Document Type: Article

References (67)

1. Adhikari, B., Howes, T., Lecomte, D., Bhandari, B.R., A glass transition temperature approach for the prediction of the surface stickiness of a drying droplet during spray drying. Powder Technol. 149 (2005), 168–179.
2. Adler, M., Lee, G., Stability and surface activity of lactate dehydrogenase in spray-dried trehalose. J. Pharm. Sci. 88 (1999), 199–208.
3. Adler, M., Unger, M., Lee, G., Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant. Pharm. Res. 17 (2000), 863–870.
4. Aquino, R.P., Prota, L., Auriemma, G., Santoro, A., Mencherini, T., Colombo, G., Russo, P., Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int. J. Pharm. 426 (2012), 100–107.
5. Arbex, M.A., Varella, M.D.C.L., Siqueira, H.R.D., Mello, F.A.F.D., Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J. Bras. Pneumol. 36 (2010), 626–640.
6. Atkins, P., Dry powder inhalers: an overview. Respir. Care, 2005, 1304–1312.
7. BP, C., British Pharmacopoeia. 2015, Stationery Office, London, England.
8. Barbosa-Cánovas, G.V., Ortega-Rivas, E., Juliano, P., Yan, H., Mixing. Food Powders: Physical Properties, Processing and Functionality, 2005, Kluwer Academic, New York.
9. Begat, P., Morton, D.A., Staniforth, J.N., Price, R., The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics. Pharm. Res. 21 (2004), 1826–1833.
10. Behboudi-Jobbehdar, S., Soukoulis, C., Yonekura, L., Fisk, I., Optimization of spray-drying process conditions for the production of maximally viable microencapsulated L. acidophilus NCIMB 701748. Drying Technol. 31 (2013), 1274–1283.
11. Chan, J.G., Tyne, A.S., Pang, A., Chan, H.K., Young, P.M., Britton, W.J., Duke, C.C., Traini, D., A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Pharm. Res. 31 (2014), 1239–1253.
12. Chan, J.G.Y., Duke, C.C., Ong, H.X., Chan, J.C.Y., Tyne, A.S., Chan, H.K., Britton, W.J., Young, P.M., Traini, D., A novel inhalable form of rifapentine. J. Pharm. Sci. 103 (2014), 1411–1421.
13. Chang, Y.-X., Yang, J.-J., Pan, R.-L., Chang, Q., Liao, Y.-H., Anti-hygroscopic effect of leucine on spray-dried herbal extract powders. Powder Technol. 266 (2014), 388–395.
14. Chen, K.H., Mueannoom, W., Gaisford, S., Kett, V.L., Investigation into the effect of varying L-leucine concentration on the product characteristics of spray-dried liposome powders. J. Pharm. Pharmacol. 64 (2012), 1412–1424.
15. Chew, N.Y., Shekunov, B.Y., Tong, H.H., Chow, A.H., Savage, C., Wu, J., Chan, H.K., Effect of amino acids on the dispersion of disodium cromoglycate powders. J. Pharm. Sci. 94 (2005), 2289–2300.
16. Chew, N.Y.K., Tang, P., Chan, H.-K., Raper, J.A., How much particle surface corrugation is sufficient to improve aerosol performance of powders?. Pharm. Res. 22 (2005), 148–152.
17. Claus, S., Weiler, C., Schiewe, J., Friess, W., How can we bring high drug doses to the lung?. Eur. J. Pharm. Biopharm. 86 (2014), 1–6.
18. Cruz, L., Fattal, E., Tasso, L., Freitas, G.C., Carregaro, A.B., Guterres, S.S., Pohlmann, A.R., Tsapis, N., Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J. Controlled Release 152 (2011), 370–375.
19. Das, S., Larson, I., Young, P., Stewart, P., Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation. J. Pharm. Sci. 98 (2009), 1015–1027.
20. Das, S., Luu, J., Morton, D., Stewart, P., A novel approach to develop high dose drug alone inhaler. J. Aerosol Med. Pulm. Drug Deliv, 2014, Mary Ann Liebert, Inc, 140 Huguenot Street, 3rd Fl, New Rochelle, NY 10801 USA A6-A6.
21. Das, S., Tucker, I., Stewart, P., Inhaled dry powder formulations for treating tuberculosis. Curr. Drug Deliv. 12 (2015), 26–39.
22. Dunber, C.A., Hickey, A.J., Holzner, P., Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder Part. J. 16 (1998), 7–45.
23. du Toit, L.C., Pillay, V., Danckwerts, M.P., Tuberculosis chemotherapy: current drug delivery approaches. Respir. Res., 7, 2006, 118.
24. Eedara, B.B., Tucker, I.G., Das, S.C., Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis. Int. J. Pharm. 506 (2016), 174–183.
25. Fourie, P.B., Germishuizen, W.A., Wong, Y.L., Edwards, D.A., Spray drying TB vaccines for pulmonary administration. Expert Opin. Biol. Ther. 8 (2008), 857–863.
26. Glover, W., Chan, H.K., Eberl, S., Daviskas, E., Verschuer, J., Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int. J. Pharm. 349 (2008), 314–322.
27. Hickey, A.J., Lung deposition and clearance of pharmaceutical aerosols: what can be learned from inhalation toxicology and industrial hygiene?. Aerosol Sci. Technol. 18 (1993), 290–304.
28. Hoppentocht, M., Akkerman, O.W., Hagedoorn, P., Frijlink, H.W., de Boer, A.H., The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer family. Eur. J. Pharm. Biopharm. 90 (2015), 8–15.
29. Islam, N., Gladki, E., Dry powder inhalers (DPIs)–a review of device reliability and innovation. Int. J. Pharm. 360 (2008), 1–11.
30. Jouppila, K., Roos, Y.H., Crystallization: measurements, data, and prediction. Rahman, M.S., (eds.) Food Properties Handbook, 2008, CRC press, Florida, 323–346.
31. Kaialy, W., Nokhodchi, A., Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations. AAPS J. 15 (2013), 728–743.
32. Kwok, P.C., Grabarek, A., Chow, M.Y., Lan, Y., Li, J.C., Casettari, L., Mason, A.J., Lam, J.K., Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. Int. J. Pharm. 491 (2015), 367–374.
33. Li, H.Y., Seville, P.C., Williamson, I.J., Birchall, J.C., The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J. Gene Med. 7 (2005), 343–353.
34. Mangal, S., Meiser, F., Lakio, S., Morton, D., Larson, I., The role of physico-chemical and bulk characteristics of co-spray dried L-leucine and polyvinylpyrrolidone on glidant and binder properties in interactive mixtures. Int. J. Pharm. 479 (2015), 338–348.
35. Mangal, S., Meiser, F., Tan, G., Gengenbach, T., Denman, J., Rowles, M.R., Larson, I., Morton, D.A., Relationship between surface concentration of L-leucine and bulk powder properties in spray dried formulations. Eur. J. Pharm. Biopharm. 94 (2015), 160–169.
36. Meenach, S.A., Anderson, K.W., Zach Hilt, J., McGarry, R.C., Mansour, H.M., Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur. J. Pharm. Sci. 49 (2013), 699–711.
37. Mendelman, P.M., Smith, A.L., Levy, J., Weber, A., Ramsey, B., Davis, R.L., Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum 1–3. Am. Rev. Respir. Dis. 132 (1985), 761–765.
38. Migliori, G., Hopewell, P., Blasi, F., Spanevello, A., Raviglione, M., Improving the TB case management: the international standards for tuberculosis care. Eur. Respir. J. 28 (2006), 687–690.
39. Millard, J., Ugarte-Gil, C., Moore, D.A., Multidrug resistant tuberculosis. BMJ, 350, 2015, h882.
40. Mishra, M., Mishra, B., Formulation optimization and characterization of spray dried microparticles for inhalation delivery of doxycycline hyclate. Yakugaku Zasshi., 131, 2011, 1813.
41. Mortensen, N.P., Durham, P., Hickey, A.J., The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy. J. Microencapsul. 31 (2014), 785–795.
42. Mullarney, M.P., Beach, L.E., Davé, R.N., Langdon, B.A., Polizzi, M., Blackwood, D.O., Applying dry powder coatings to pharmaceutical powders using a comil for improving powder flow and bulk density. Powder Technol. 212 (2011), 397–402.
43. Nuermberger, E.L., Yoshimatsu, T., Tyagi, S., Williams, K., Rosenthal, I., O'Brien, R.J., Vernon, A.A., Chaisson, R.E., Bishai, W.R., Grosset, J.H., Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170 (2004), 1131–1134.
44. Palaniandy, S., Azizli, K.A.M., Mechanochemical effects on talc during fine grinding process in a jet mill. Int. J. Miner. Process. 92 (2009), 22–33.
45. Pham, D.D., Fattal, E., Tsapis, N., Pulmonary drug delivery systems for tuberculosis treatment. Int. J. Pharm. 478 (2015), 517–529.
46. Piao, H., McIntyre, N.S., Adventitious carbon growth on aluminium and gold-aluminium alloy surfaces. Surf. Interface Anal. 33 (2002), 591–594.
47. Pilcer, G., Amighi, K., Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392 (2010), 1–19.
48. Price, R., Young, P., Edge, S., Staniforth, J., The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int. J. Pharm. 246 (2002), 47–59.
49. Prota, L., Santoro, A., Bifulco, M., Aquino, R.P., Mencherini, T., Russo, P., Leucine enhances aerosol performance of naringin dry powder and its activity on cystic fibrosis airway epithelial cells. Int. J. Pharm. 412 (2011), 8–19.
50. Seville, P.C., Learoyd, T.P., Li, H.Y., Williamson, I.J., Birchall, J.C., Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 178 (2007), 40–50.
51. Seville, P.C., Li, H., Learoyd, T.P., Spray-dried powders for pulmonary drug delivery. Crit. Rev. Ther. Drug Carr. Syst., 24, 2007.
52. Shur, J., Nevell, T.G., Ewen, R.J., Price, R., Smith, A., Barbu, E., Conway, J.H., Carroll, M.P., Shute, J.K., Smith, J.R., Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. J. Pharm. Sci. 97 (2008), 4857–4868.
53. Smith, I.J., Parry-Billings, M., The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. 16 (2003), 79–95.
54. Sou, T., Kaminskas, L.M., Nguyen, T.H., Carlberg, R., McIntosh, M.P., Morton, D.A., The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur. J. Pharm. Biopharm. 83 (2013), 234–243.
55. Suarez, S., Hickey, A.J., Drug properties affecting aerosol behavior. Respir. Care 45 (2000), 652–666.
56. Thai, A., Xiao, J., Ammit, A.J., Rohanizadeh, R., Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims. Int. J. Pharm. 389 (2010), 41–52.
57. Tian, G., Longest, P.W., Li, X., Hindle, M., Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J. Aerosol Med. Pulm. Drug Deliv. 26 (2013), 248–265.
58. Vehring, R., Pharmaceutical particle engineering via spray drying. Pharm. Res. 25 (2008), 999–1022.
59. WHO, Treatment of Tuberculosis: Guidelines. 2010, World Health Organization.
60. WHO, Global Tuberculosis Report 2015., 2015 Geneva, Switzerland.
61. Wahl, M., Kirsch, R., Bröckel, U., Trapp, S., Bottlinger, M., Caking of urea prills. Chem. Eng. Technol. 29 (2006), 674–678.
62. Weers, J., Clark, A., Challoner, P., High Dose Inhaled Powder Delivery: Challenges and Techniques, Respiratory Drug Delivery IX. 2004, Amy Davis Biggs, River Grove, IL, 281–288.
63. Wu, X., Hayes, D. Jr., Zwischenberger, J.B., Kuhn, R.J., Mansour, H.M., Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des. Dev. Ther. 7 (2013), 59–72.
64. Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., Menzies, D., Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 167 (2003), 1472–1477.
65. Zeng, X.M., Martin, G.P., Marriott, C., The controlled delivery of drugs to the lung. Int. J. Pharm. 2 (1995), 149–164.
66. Zhou, Q.T., Qu, L., Larson, I., Stewart, P.J., Morton, D.A., Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Int. J. Pharm. 394 (2010), 50–59.
67. Zijlstra, G.S., Hinrichs, W.L., de Boer, A.H., Frijlink, H.W., The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix. Eur. J. Pharm. Sci. 23 (2004), 139–149.